Title: The expression of interleukin-1# in patients with chronic hepatitis B treated with
Pegylated-interferon-# combined with tenofovir and monotherapy: analysis of 162 cases from
a single center
Version: 1 Date: 02 Mar 2023
Reviewer:  Li-Kun Wang
Reviewer's report:
The manuscript (entitled “The expression of interleukin-1# in patients with chronic hepatitis
B treated with pegylated interferon-# combined with tenofovir and monotherapy: analysis of
162 cases from a single center”) aimed to investigate the expression of IL-1# in patients with
CHB treated with Peg-IFN# combined with tenofovir (TDF) and monotherapy. The results
showed that TDF combination with Peg-IFN# expressed higher IL-1# and inhibited HBV more
effectively than monotherapy in vitro. The increase of serum IL-1# level may improve the
antiviral efficacy of NAs combination with Peg-IFN-#. This may provide a new therapeutic
tactic for patients with CHB, especially for those patients who can not respond well to antiviral
therapy.
Question:
There are several lexical repetition and grammatical mistakes in the text. Please revise and
correct them carefully.
Title: The expression of interleukin-1# in patients with chronic hepatitis B treated with
Pegylated-interferon-# combined with tenofovir and monotherapy: analysis of 162 cases from
a single center
Version: 1 Date: 02 Mar 2023
Reviewer:  Li-Kun Wang
Reviewer's report:
The manuscript (entitled “The expression of interleukin-1# in patients with chronic hepatitis
B treated with pegylated interferon-# combined with tenofovir and monotherapy: analysis of
162 cases from a single center”) aimed to investigate the expression of IL-1# in patients with
CHB treated with Peg-IFN# combined with tenofovir (TDF) and monotherapy. The results
showed that TDF combination with Peg-IFN# expressed higher IL-1# and inhibited HBV more
effectively than monotherapy in vitro. The increase of serum IL-1# level may improve the
antiviral efficacy of NAs combination with Peg-IFN-#. This may provide a new therapeutic
tactic for patients with CHB, especially for those patients who can not respond well to antiviral
therapy.
Question:
There are several lexical repetition and grammatical mistakes in the text. Please revise and
correct them carefully.
Please review this paper.
user
Title: The expression of interleukin-1# in patients with chronic hepatitis B treated with
Pegylated-interferon-# combined with tenofovir and monotherapy: analysis of 162 cases from
a single center
Version: 1 Date: 02 Mar 2023
Reviewer:  Li-Kun Wang
Reviewer's report:
The manuscript (entitled “The expression of interleukin-1# in patients with chronic hepatitis
B treated with pegylated interferon-# combined with tenofovir and monotherapy: analysis of
162 cases from a single center”) aimed to investigate the expression of IL-1# in patients with
CHB treated with Peg-IFN# combined with tenofovir (TDF) and monotherapy. The results
showed that TDF combination with Peg-IFN# expressed higher IL-1# and inhibited HBV more
effectively than monotherapy in vitro. The increase of serum IL-1# level may improve the
antiviral efficacy of NAs combination with Peg-IFN-#. This may provide a new therapeutic
tactic for patients with CHB, especially for those patients who can not respond well to antiviral
therapy.
Question:
There are several lexical repetition and grammatical mistakes in the text. Please revise and
correct them carefully.
assistant